Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 28-40

  Lam, Lloyd T ^a   Davis, R Eric ^a   Pierce, Jackie ^b   Hepperle, Michael ^b   Xu, Yajun ^b   Hottelet, Maria ^b   Nong, Yuhua ^b   Wen, Danyi ^b   Adams, Julian ^b   Dang, Lenny ^b   Staudt, Louis M ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Building 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ESTROGEN RECEPTOR; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MLX105; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; LARGE CELL LYMPHOMA; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR BINDING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOLINES; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; UP-REGULATION;

EID: 19944428834     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
2. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-62.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
5. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;348:1777-85.
6. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
7. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
8. Gugasyan R, Grumont R, Grossmann M, et al. Rel/NF-κB transcription factors: key mediators of B-cell activation. Immunol Rev 2000;176:134-40.
9. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[κ]B activity. Annu Rev Immunol 2000;18:621-63.
10. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
11. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
12. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
13. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-κB induces expression of the Bcl-2 homologue Al/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
14. Wang CY, Mayo MW, Komeluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
15. Jin R, De Smaele E, Zazzeroni F, et al. Regulation of the gadd45β promoter by NF-κB. DNA Cell Biol 2002;21:491-503.
16. De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 2001;414:308-13.
17. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999;13:400-11.
18. Grumont RJ, Strasser A, Gerondakis S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-κB regulated c-myc transcription. Mol Cell 2002;10:1283-94.
19. Hinz M, Loser P, Mathas S, et al. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001;97:2798-807.
20. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27.
21. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871-9.
22. Garg A, Aggarwal BB. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 2002;16:1053-68.
23. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
24. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
25. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: β-carbolines. Bioorg Med Chem Lett 2003;13:2419-22.
26. Hideshima T, Chauhan D, Richardson P, et al. NF-κ as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
27. Crowder C, Kopantzev E, Williams K, et al. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene 2003;22:649-59.
28. Kang E, Giri N, Wu T, et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 2001;12:1663-72.
29. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996;70:5701-5.
30. Beg AA, Ruben SM, Scheinman RI, et al. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev 1992;6:1899-913.
31. Luque I, Gelinas C. Distinct domains of IκBα regulate c-Rel in the cytoplasm and in the nucleus. Mol Cell Biol 1998;18:1213-24.
32. Franzoso G, Carlson L, Brown K, et al. Activation of the serum response factor by p65/NF-κB. EMBO J 1996;15:3403-12.
33. Ruben SM, Dillon PJ, Schreck R, et al. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-κB. Science 1991;254:11.
34. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
35. Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
36. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
37. Li X, Fang Y, Zhao X, et al. Characterization of NFκB activation by detection of green fluorescent protein-tagged IκB degradation in living cells. J Biol Chem 1999;274:21244-50.
38. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity 2001;15:375-85.
39. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
40. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42.
41. Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-κB. Cytokine Growth Factor Rev 2001;12:207-17.
42. Cabannes E, Khan O, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 1999;18:3063-70.
43. Emmerich F, Meiser M, Hummel M, et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in reed-sternberg cells. Blood 1999;94:3129-34.
44. Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53.
45. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000;191:207-12.
46. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
47. Field N, Low W, Daniels M, et al. KSHV vFLIP binds to IKK-γ to activate IKK. J Cell Sci 2003;116:3721-8. Epub 2003 Jul 30.
48. Liu L, Eby MT, Rathore N, et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Iκ B kinase complex. J Biol Chem 2002;277:13745-51. Epub 2002 Feb 5.
49. Thome M, Tschopp J. TCR-induced NF-κB activation: a crucial role for Carma1, Bcl10 and MALT1. Trends Immunol 2003;24:419-24.